376 related articles for article (PubMed ID: 27637355)
21. Romidepsin for cutaneous T-cell lymphoma.
Prince HM; Dickinson M
Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155
[TBL] [Abstract][Full Text] [Related]
22. Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases.
Poligone B; Rubio-Gonzalez B; Querfeld C
Dermatol Ther; 2019 Mar; 32(2):e12804. PubMed ID: 30549384
[TBL] [Abstract][Full Text] [Related]
23. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
24. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.
Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
Crit Rev Oncol Hematol; 2016 Mar; 99():228-40. PubMed ID: 26811014
[TBL] [Abstract][Full Text] [Related]
25. Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.
Nguyen CN; Iyer SP; Duvic M; Barde PJ; Nair A; Routhu KV; Huen AO
Invest New Drugs; 2023 Apr; 41(2):350-355. PubMed ID: 37004644
[TBL] [Abstract][Full Text] [Related]
26. Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients.
Kogge A; Volteau C; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Renaut JJ; Dréno B; Quéreux G
Acta Derm Venereol; 2015 Jan; 95(1):72-7. PubMed ID: 24806744
[TBL] [Abstract][Full Text] [Related]
27. Romidepsin for cutaneous T-cell lymphoma.
Prince HM; Dickinson M; Khot A
Future Oncol; 2013 Dec; 9(12):1819-27. PubMed ID: 24295412
[TBL] [Abstract][Full Text] [Related]
28. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
[TBL] [Abstract][Full Text] [Related]
30. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
31. Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions.
Akilov OE; Grant C; Frye R; Bates S; Piekarz R; Geskin LJ
Br J Dermatol; 2012 Jul; 167(1):194-7. PubMed ID: 22372971
[TBL] [Abstract][Full Text] [Related]
32. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
Querfeld C; Zain J; Rosen ST
Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
[TBL] [Abstract][Full Text] [Related]
33. Mycosis fungoides and the Sézary syndrome.
Foss F
Curr Opin Oncol; 2004 Sep; 16(5):421-8. PubMed ID: 15314509
[TBL] [Abstract][Full Text] [Related]
34. Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma.
Chung CG; Poligone B
Dermatol Clin; 2015 Oct; 33(4):787-805. PubMed ID: 26433850
[TBL] [Abstract][Full Text] [Related]
35. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
Duvic M; Dummer R; Becker JC; Poulalhon N; Ortiz Romero P; Grazia Bernengo M; Lebbé C; Assaf C; Squier M; Williams D; Marshood M; Tai F; Prince HM
Eur J Cancer; 2013 Jan; 49(2):386-94. PubMed ID: 22981498
[TBL] [Abstract][Full Text] [Related]
36. Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sézary syndrome.
Jothishankar B; Almazan T; Kim Y; Liauw S; Smith S; Kline J; Abdulla F
Br J Haematol; 2019 Jul; 186(2):377-379. PubMed ID: 30937886
[No Abstract] [Full Text] [Related]
37. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
Wang Z; Ma J; Zhang H; Ramakrishna R; Mintzlaff D; Mathes DW; Pomfret EA; Lucia MS; Gao D; Haverkos BM; Wang Z
FEBS Open Bio; 2023 Jul; 13(7):1309-1319. PubMed ID: 37157185
[TBL] [Abstract][Full Text] [Related]
38. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.
Lyseng-Williamson KA; Yang LP
Am J Clin Dermatol; 2012 Feb; 13(1):67-71. PubMed ID: 22066664
[TBL] [Abstract][Full Text] [Related]
39. Pentostatin treatment of cutaneous T-cell lymphoma.
Dearden C; Matutes E; Catovsky D
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):37-40. PubMed ID: 10887643
[TBL] [Abstract][Full Text] [Related]
40. Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma.
Poligone B; Lin J; Chung C
Core Evid; 2011; 6():1-12. PubMed ID: 21468238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]